Abstract
Germline variation may influence anti-tumour immune responses. Recent studies suggest that polygenic scores (PGS) for autoimmune disease risk are associated with immune-related adverse events in patients (pts) treated with anti-PD(L)-1 therapy (anti-PD1) but the role of PGS in melanoma remains unexplored. We evaluated associations between PGS for vitiligo (VIT) and hypothyroidism (HYPOT) and melanoma molecular and clinical traits.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
